Patents by Inventor Xiao-Jun Ma

Xiao-Jun Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078528
    Abstract: The invention relates to methods of in situ detection of a nucleic acid variation of a target nucleic acid in a sample, including single nucleotide variations, multi-nucleotide variations or splice sites. The method can comprise the steps of contacting the sample with a probe that detects the nucleic acid variation or splice site and a neighbor probe; contacting the sample with pre-amplifiers that bind to the nucleic acid variation probe or splice site probe and neighbor probe, respectively; contacting the sample with a collaboration amplifier that binds to the pre-amplifiers; and contacting the sample with a label probe system, wherein hybridization of the components forms a signal generating complex (SGC) comprising a target nucleic acid with the nucleic acid variation or splice site, the probes and amplifiers; and detecting in situ signal from the SGC on the sample.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 3, 2021
    Assignee: ADVANCED CELL DIAGNOSTICS, INC.
    Inventors: Yuling Luo, Xingyong Wu, Liuliu Pan, Xiaoming Wang, Xiao-Jun Ma, Nan Su, Steve Chen
  • Patent number: 11021754
    Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: June 1, 2021
    Assignee: Biotheranostics, Inc.
    Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis Sgroi
  • Publication number: 20210032690
    Abstract: The present invention relates to detection of nucleic acids and provides a composition comprising a Signal Generating Complex, wherein the composition comprises: (A) a pair of target probes (TPs), wherein a first TP of the pair of TPs comprises a nucleic acid sequence comprising two segments; (B) a pair of base PPAs comprising the first and second base PPAs, wherein the first base PPA comprises a nucleic acid sequence comprising three segments; (C) a set of extension PPAs comprising the first and second extension PPAs, wherein the first extension PPA comprises a nucleic acid sequence comprising two segments; (D) a plurality of pre-amplifiers (PAs), wherein the PAs comprise a nucleic acid sequence comprising three segments; (E) a plurality of amplifiers (AMPs), wherein the AMPs comprise a nucleic acid sequence comprising two segments; and (F) a plurality of label probes (LPs), wherein the LPs comprise a nucleic acid sequence comprising two segments.
    Type: Application
    Filed: April 8, 2019
    Publication date: February 4, 2021
    Inventors: Yuling LUO, Xiao-Jun MA, Steve CHEN, Nan SU, Emerald DOOLITTLE, Bingqing ZHANG, Xiaoming WANG, Xingyong WU, Xiao Yan PIMENTEL, Helen JARNAGIN
  • Publication number: 20200190597
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 18, 2020
    Inventors: Mark G. Erlander, Xiao-Jun Ma
  • Publication number: 20200095642
    Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.
    Type: Application
    Filed: May 6, 2019
    Publication date: March 26, 2020
    Inventors: Xiao-Jun Ma, Dennis C. Sgroi, Mark G. Erlander
  • Patent number: 10538816
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 21, 2020
    Assignee: Biotheranostics, Inc.
    Inventors: Mark G. Erlander, Xiao-Jun Ma
  • Patent number: 10329624
    Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: June 25, 2019
    Assignees: Biotheranostics, Inc., The General Hospital Corporation
    Inventors: Xiao-Jun Ma, Dennis C. Sgroi, Mark G. Erlander
  • Patent number: 10206171
    Abstract: Methods and systems for scheduling wake/sleep cycles by a central device in a wireless network that have at least one mobile device include determining a system reference cycle as a minimum value of a delay constraint on a real-time service for each mobile device of the at least one mobile device that has a real-time service. A wake/sleep cycle length is attributed to each mobile device. The wake/sleep cycle length is an integer multiple of the system reference cycle such that a wake/sleep cycle length of a first mobile device is different from that of a second mobile device. A sleep period and a wake period are assigned within the wake/sleep cycle of each mobile device. The wake/sleep cycle of each mobile device is arranged to avoid collision of the wake period with those of other mobile devices.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: February 12, 2019
    Assignee: INTERDIGITAL CE PATENT HOLDINGS
    Inventors: Ning Liao, Jian Feng Chen, Xiao Jun Ma
  • Publication number: 20180291461
    Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
    Type: Application
    Filed: November 8, 2017
    Publication date: October 11, 2018
    Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis Sgroi
  • Publication number: 20180127834
    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 10, 2018
    Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
  • Publication number: 20180073085
    Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: April 28, 2017
    Publication date: March 15, 2018
    Inventors: Mark ERLANDER, Xiao-Jun MA
  • Publication number: 20180051342
    Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.
    Type: Application
    Filed: March 27, 2017
    Publication date: February 22, 2018
    Inventors: Xiao-Jun MA, Chin-Lee WU, Mark G. ERLANDER, William Scott MCDOUGAL
  • Patent number: 9856533
    Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: January 2, 2018
    Assignees: Biotheranostics, Inc., The General Hospital Corporation
    Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
  • Publication number: 20170286596
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: December 2, 2016
    Publication date: October 5, 2017
    Inventors: Mark G. ERLANDER, Xiao-Jun Ma
  • Publication number: 20170268064
    Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Application
    Filed: December 2, 2016
    Publication date: September 21, 2017
    Inventors: Mark G. ERLANDER, Xiao-Jun Ma
  • Patent number: 9686570
    Abstract: It is provided a method for synchronizing content playback at the presentation level, wherein, a first content is presented on a first device and a second content that is the same as or correlated with the first content is presented on a second device. The method comprises steps of receiving status messages from the first device and the second device, wherein the status messages comprise information about playback positions of the first content and the second content currently being playbacked at the presentation level of the first device and the second device; and in response to differences between playback positions of the first content and the second content comprised in the status messages being above a threshold value, performing adjustment to maintain difference of playback positions of the first content and the second content at the presentation level of the first device and the second device below the threshold value.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: June 20, 2017
    Assignee: THOMSON LICENSING
    Inventors: Jian Feng Chen, Xiao Jun Ma
  • Patent number: 9670553
    Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: June 6, 2017
    Assignee: bioTheranostics, Inc.
    Inventors: Mark Erlander, Xiao-Jun Ma
  • Patent number: 9635075
    Abstract: A user assigns a major and minor channel number combination to a media service which does not have such a pre-existing combination, where such a media service is accessed by using such a channel combination without having to resort to the typical means of accessing the media service, such as using a web site URL or radio frequency. Optionally, the invention will automatically update the minor numbers associated with a media service when older versions of the media service become unavailable.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: April 25, 2017
    Assignee: Thomson Licensing DTV
    Inventors: Xiao Jun Ma, Jun Li, Lin Du, Jian Ping Song
  • Patent number: 9628675
    Abstract: An object tracking and recognition system are provided and comprise a video device for getting the image information of an object in the detection range of the object tracking and recognition system; and a radio frequency identification (RFID) device for detecting signal strength of a radio frequency (RF) tag of the object; wherein the video device is turned on to get the image information of the object upon the detected signal strength reaching a predetermined signal strength threshold.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: April 18, 2017
    Assignee: Thomson Licensing
    Inventors: Wei Zhou, Jun Li, Xiao Jun Ma
  • Publication number: 20170101672
    Abstract: The invention relates to methods of in situ detection of a nucleic acid variation of a target nucleic acid in a sample, including single nucleotide variations, multi-nucleotide variations or splice sites. The method can comprise the steps of contacting the sample with a probe that detects the nucleic acid variation or splice site and a neighbor probe; contacting the sample with pre-amplifiers that bind to the nucleic acid variation probe or splice site probe and neighbor probe, respectively; contacting the sample with a collaboration amplifier that binds to the pre-amplifiers; and contacting the sample with a label probe system, wherein hybridization of the components forms a signal generating complex (SGC) comprising a target nucleic acid with the nucleic acid variation or splice site, the probes and amplifiers; and detecting in situ signal from the SGC on the sample.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 13, 2017
    Inventors: Yuling Luo, Xingyong Wu, Liuliu Pan, Xiaoming Wang, Xiao-Jun Ma, Nan Su, Steve Chen